Want to see SE:BONEX full AI Analyst Report?
BONEX Stock Chart & Stats
kr223.60
kr4.40(2.01%)
At close: 4:00 PM EDT
kr223.60
kr4.40(2.01%)
Day’s Range― - ―
52-Week Rangekr165.00 - kr323.00
Previous CloseN/A
Volume136.56K
Average Volume (3M)318.62K
Market Cap
kr14.73B
Enterprise Valuekr13.69K
Total Cash (Recent Filing)kr434.31M
Total Debt (Recent Filing)kr10.13M
Price to Earnings (P/E)69.8
Beta0.70
Next Earnings
Oct 22, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.24
Shares Outstanding65,859,190
10 Day Avg. Volume295,837
30 Day Avg. Volume318,624
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio57.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.92
Revenue Forecast (FY)kr1.49B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthStrong current growth and reiterated full-year guidance indicate expanding adoption of BONESUPPORT’s products. The momentum supports continued operating leverage and provides a durable foundation for scaling the commercial platform.
High Margins And Improved Cash GenerationVery high gross margins and strong recent cash conversion show an economically attractive, increasingly scalable business model. If maintained, this profitability can fund commercial expansion while reducing reliance on external capital.
Strong U.S. And Antibiotic-Eluting Product AdoptionRapid U.S. expansion and strong growth in antibiotic-eluting products demonstrate meaningful clinical and commercial adoption. Broader use of these differentiated products can deepen market penetration and support sustained revenue growth.
Bears Say
Growth Deceleration And Historical VolatilityAlthough growth remains strong, deceleration raises the risk that prior expansion rates will not persist. Historical volatility in earnings and cash generation also means investors must verify that the recent profitability improvement is durable.
Regulatory And Reimbursement UncertaintyFuture growth opportunities depend partly on regulatory and reimbursement milestones that are outside management’s control. Delays or unfavorable outcomes could restrict indication expansion, postpone adoption, and limit the contribution of new products.
Rising Commercial Cost BaseHigher commercial spending may be necessary to capture growth, but it can pressure reported margins and cash conversion if productivity lags. Account-level usage restrictions could further increase the effort required to sustain U.S. momentum.
BONESUPPORT HOLDING AB News
BONEX FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was kr165.00 and its highest was kr323.00 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is kr14.73B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Oct 22, 2026 which is in 63 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Jul 16, 2026. The company reported kr1.23 earnings per share for the quarter, beating the consensus estimate of kr1.13 by kr0.1.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 1.29.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of kr1.23 in its last earnings report, beating expectations of kr1.13. Following the earnings report the stock price went down -5.834%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in SE:BONEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
BONEX Company Deck
BONEX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong revenue growth (30% FX-adjusted), high adjusted margins (29%), solid cash generation and pronounced U.S. launch momentum for CERAMENT G. Material positives include regulatory progress, proposed CMS reimbursement improvements, and healthy EUROW performance. Headwinds include a small set of U.S. accounts temporarily restricting usage (modestly dampening growth), higher commercial and incentive costs, minor gross margin impacts from write-downs and tariffs, and uncertainty around the timing of regulatory approvals and study publications. On balance the company's growth trajectory and scalable profitability outweigh the transitory challenges discussed.View all SE:BONEX earnings summaries